MX346533B - Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides). - Google Patents

Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).

Info

Publication number
MX346533B
MX346533B MX2013009760A MX2013009760A MX346533B MX 346533 B MX346533 B MX 346533B MX 2013009760 A MX2013009760 A MX 2013009760A MX 2013009760 A MX2013009760 A MX 2013009760A MX 346533 B MX346533 B MX 346533B
Authority
MX
Mexico
Prior art keywords
disease
hyperalgesia
crystalline forms
osteoarthritis
receptor
Prior art date
Application number
MX2013009760A
Other languages
English (en)
Spanish (es)
Other versions
MX2013009760A (es
Inventor
c blackburn Anthony
Han Sangdon
M Jones Robert
Garrido Montalban Anthony
B Pal Biman
Karyn Rueter Jaimie
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2013009760A publication Critical patent/MX2013009760A/es
Publication of MX346533B publication Critical patent/MX346533B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013009760A 2011-02-25 2012-02-24 Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides). MX346533B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (2)

Publication Number Publication Date
MX2013009760A MX2013009760A (es) 2014-06-11
MX346533B true MX346533B (es) 2017-03-14

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009760A MX346533B (es) 2011-02-25 2012-02-24 Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).

Country Status (20)

Country Link
US (4) US9458136B2 (https=)
EP (3) EP4166552B1 (https=)
JP (1) JP5945554B2 (https=)
KR (1) KR102036932B1 (https=)
CN (1) CN103608343B (https=)
AU (1) AU2012222146B2 (https=)
BR (1) BR112013021549B1 (https=)
CA (1) CA2827057C (https=)
CL (1) CL2013002436A1 (https=)
CO (1) CO6852066A2 (https=)
DK (1) DK3395812T3 (https=)
EA (1) EA035989B1 (https=)
ES (1) ES2932441T3 (https=)
IL (1) IL227782A (https=)
MX (1) MX346533B (https=)
MY (1) MY165767A (https=)
PH (1) PH12013501726A1 (https=)
SG (1) SG192817A1 (https=)
WO (1) WO2012116276A1 (https=)
ZA (1) ZA201306402B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2770866C (en) 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US9458136B2 (en) * 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
CA3019842A1 (en) * 2016-04-10 2017-10-19 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TW202330496A (zh) 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
AU2002357114B2 (en) 2001-12-07 2008-07-24 Virginia Commonwealth University Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
JP2008505965A (ja) 2004-07-12 2008-02-28 カディラ ヘルスケア リミティド カンナビノイド受容体修飾因子としての三環式ピラゾール誘導体
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体,含有该配体的药物组合物及其制备方法
CA2613678A1 (en) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
PT2081572E (pt) 2006-07-04 2010-05-17 Janssen Pharmaceutica Nv Agonistas de canabinóides de benzimidazolo com um grupo heterocíclico substituído
CA2664310A1 (en) 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
WO2008053341A2 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
WO2008064054A2 (en) 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EP2170350B1 (en) 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA2770866C (en) 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) * 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
US9458136B2 (en) * 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators

Also Published As

Publication number Publication date
PH12013501726A1 (en) 2014-01-13
JP5945554B2 (ja) 2016-07-05
EA035989B1 (ru) 2020-09-09
AU2012222146A1 (en) 2013-09-19
US11560369B2 (en) 2023-01-24
SG192817A1 (en) 2013-09-30
EP3395812B8 (en) 2022-11-02
US20170144993A1 (en) 2017-05-25
BR112013021549A2 (pt) 2016-11-01
US10183930B2 (en) 2019-01-22
AU2012222146B2 (en) 2017-05-11
EP3395812A1 (en) 2018-10-31
MY165767A (en) 2018-04-23
CL2013002436A1 (es) 2014-01-24
US20140135345A1 (en) 2014-05-15
CO6852066A2 (es) 2014-01-30
ES2932441T3 (es) 2023-01-19
IL227782A (en) 2017-02-28
US9458136B2 (en) 2016-10-04
US10981895B2 (en) 2021-04-20
JP2014506602A (ja) 2014-03-17
CN103608343A (zh) 2014-02-26
KR20140025353A (ko) 2014-03-04
US20190308952A1 (en) 2019-10-10
EA201391233A1 (ru) 2014-02-28
ZA201306402B (en) 2022-03-30
CN103608343B (zh) 2019-02-01
EP4166552B1 (en) 2025-03-19
US20210380560A1 (en) 2021-12-09
KR102036932B1 (ko) 2019-10-25
EP4166552A1 (en) 2023-04-19
BR112013021549B1 (pt) 2022-01-11
EP3395812B1 (en) 2022-09-28
NZ614787A (en) 2014-08-29
MX2013009760A (es) 2014-06-11
CA2827057C (en) 2022-06-07
DK3395812T3 (da) 2022-11-28
CA2827057A1 (en) 2012-08-30
EP2678330A1 (en) 2014-01-01
WO2012116276A1 (en) 2012-08-30
IL227782A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
MX346533B (es) Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).
ZA202205142B (en) Cannabinoid receptor modulators
WO2011075534A3 (en) Purification of isoprene from renewable resources
AU2011343222B2 (en) Novel 7B-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid
JP2013533314A5 (https=)
MX347947B (es) Metodo y sistema para preparar cloruro de hidrogeno de alta pureza.
WO2008155534A9 (en) Neurosteroid compounds
WO2013060614A9 (de) Farbstabile härterzusammensetzungen enthaltend polyisocyanate (cyclo)aliphatischer diisocyanate
WO2012054616A3 (en) Synthesis of methylene malonates substantially free of impurities
PH12012501918A1 (en) Process for preparation of dopo-derived compounds and compositions thereof
BR112012019156A2 (pt) processo para recuperação de etanol
MX2013007667A (es) Procesos y sistemas para aislar enzimaticamente lignina y otros bioproductos de plantas herbaceas.
WO2012104244A8 (de) Verfahren zur fermentativen herstellung von 2,3-butandiol
WO2012045022A3 (en) Metabolic engineering of clostridium tyrobutyricum for butanol production
MX2012004559A (es) Metodos y sistemas para tratamiento farmacogenomico de condiciones cardiovasculares.
IN2014MN01003A (https=)
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
AU2007307111A1 (en) High-purity large-scale preparation of stannsoporfin
WO2010066680A3 (de) Verfahren zur abtrennung metallischer verunreinigungen
MX2014005561A (es) Suavizante de telas.
WO2010090536A3 (en) Plant transformation using dna minicircles
BR112012019310A2 (pt) processos para purificação de etanol
WO2011049334A3 (ko) 식물병에 대해 저항성을 증진시키는 OsLRP 유전자 및 이의 용도
WO2013072592A3 (fr) Épaississants non ioniques associatifs contenant des alkyls cyclohexylols alkoxyles, leurs utilisations et formulations les contenant
WO2013040572A8 (en) Compositions and methods for the production and use of human cholinesterases

Legal Events

Date Code Title Description
FG Grant or registration